Invesco
CUE icon

Invesco’s Cue Biopharma CUE Stock Holding History

Invesco’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-507
Closed -$28.7K – 3897
2024
Q1 		$28.7K Sell
507
-4
-0.8% -$282 ﹤0.01% 3832
2023
Q4 		$40.5K Sell
511
-77
-13% -$5.5K ﹤0.01% 3765
2023
Q3 		$40.6K Hold
588
– – ﹤0.01% 3815
2023
Q2 		$64.4K Buy
+588
New +$69.1K ﹤0.01% 3795
2022
Q2 		– Sell
-415
Closed -$60K – 4062
2022
Q1 		$60K Sell
415
-4
-1% -$848 ﹤0.01% 3913
2021
Q4 		$142K Sell
419
-6
-1% -$2.32K ﹤0.01% 3847
2021
Q3 		$186K Buy
+425
New +$148K ﹤0.01% 3828
2020
Q2 		– Sell
-1,465
Closed -$623K – 3651
2020
Q1 		$623K Sell
1,465
-501
-25% -$243K ﹤0.01% 2959
2019
Q4 		$937K Buy
+1,966
New +$618K ﹤0.01% 3027

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Invesco's CUE Position: Q2 2024 in Review

Invesco sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 507 shares — an estimated $28.7K sold.

Invesco first reported a position in CUE in Q4 2019 and held it in 9 quarters. The position peaked at $937K in Q4 2019. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Invesco reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Invesco sold 507 Cue Biopharma shares in Q2 2024, an estimated $28.7K.
  • Invesco first reported a position in Cue Biopharma in Q4 2019 and held it in 9 quarters.
  • Invesco's Cue Biopharma position peaked at $937K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.